Original researchComparison of the efficacy of ciclesonide 160 μg QDand budesonide 200 μg BID in adults with persistent asthma: A phase III, randomized, double-dummy, open-label study
References (29)
Side effects of inhaled corticosteroids
J Allergy Clin Immunol
(1998)- et al.
Relationship between adherence to inhaled corticosteroids and poor outcomes among adults with asthma
J Allergy Clin Immunol
(2004) - et al.
Improving patient compliance with asthma therapy
Respir Med
(2000) Overcoming barriers to nonadherence in asthma treatment
J Allergy Clin Immunol
(2002)- et al.
Switching asthma patients to a once-daily inhaled steroid improves compliance and reduces healthcare costs
Primary Care Respir J
(2005) - et al.
Inhaled corticosteroids: Past lessons and future issues
J Allergy Clin Immunol
(2003) - et al.
Formation of fatty acid conjugates of ciclesonide active metabolite in the rat lung after 4-week inhalation of ciclesonide
Pulm Pharmacol Ther
(2005) Pharmacokinetic and pharmacodynamic properties of inhaled corticosteroids in relation to efficacy and safety
Respir Med
(1997)Global strategy for asthma management and prevention
NIH publication 02-3659
(2003)- et al.
Systemic effect comparisons of six inhaled corticosteroid preparations
Am J Respir Crit Care Med
(2002)
Once-daily inhaled corticosteroids for the treatment of asthma
Curr Opin Pulm Med
PK/PD of inhaled corticosteroids: The risk/benefit of inhaled ciclesonide
J Allergy Clin Immunol
High lung deposition of 99mTc-labelled ciclesonide administered via HFA-MDI to asthma patients
Eur Respir J
Esterases involved in the hydrolysis of ciclesonide in human tissues
Eur Respir J
Cited by (52)
Evaluation of bioadhesive gels for local action in the esophagus
2023, International Journal of PharmaceuticsClinical trials and future perspectives of antiinflammatory agents
2023, Recent Developments in Anti-Inflammatory TherapyCiclesonide: A Pro-Soft Drug Approach for Mitigation of Side Effects of Inhaled Corticosteroids
2016, Journal of Pharmaceutical SciencesCitation Excerpt :Ciclesonide is a novel pro-soft drug ICS, which gets activated to its active drug, called desisobutyryl-ciclesonide (des-CIC) by pulmonary esterases in the lungs, exert its therapeutic actions in the lungs and gets inactivated in a controlled metabolism.4,14 It possesses several PK and PD properties which leads to an advantageous safety profile and fewer oropharyngeal and systemic side effects in comparison to existing ICSs such as beclomethasone dipropionate and fluticasone propionate.27,28 The unique PK and PD properties of ciclesonide due to its design as a soft drug are explained in the following sections.
Asthma outcomes: Exacerbations
2012, Journal of Allergy and Clinical ImmunologyComparison of the effect of low-dose ciclesonide and fixed-dose fluticasone propionate and salmeterol combination on long-term asthma control
2011, ChestCitation Excerpt :It seems unlikely that the once-daily dosage of ICS in the present study would have caused the difference seen in the time to first asthma exacerbation because several studies have shown clinical benefits, including reduced exacerbation rates in patients with mild to moderate asthma, with ciclesonide once daily.4,5,7,10 Moreover, once-daily ciclesonide has shown consistent and comparable clinical efficacy with other ICSs, including budesonide24,25 and fluticasone propionate,5,10,26 in improving pulmonary function, controlling asthma symptoms, and reducing rescue medication use and exacerbations. We acknowledge that mild symptoms may not equate mild pathophysiology.
Efficacy and safety of ciclesonide in the treatment of 24,037 asthmatic patients in routine medical care
2011, Respiratory MedicineCitation Excerpt :A placebo-controlled study by Langdon et al. also noted significant improvements in FEV1 (significant increases of +0.13 l with 80 μg and +0.19 l with 320 μg ciclesonide versus placebo after 3 months) and PEF in patients treated with 80 μg or 320 μg daily ciclesonide for 3 months compared to placebo.12 Other 3-month, randomized, double-blind, active controlled studies also demonstrated a significant increase in FEV1 from baseline to study end with non-inferiority to budesonide and fluticasone.37–39 Similarly, the mean PEF increased in the course of the treatment with 160 μg ciclesonide by 14% which is comparable to the previously reported clinical trials with 22.4 l/min with half the dose.12